A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
Price : $35 *
At a glance
- Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 Jul 2013 New trial record
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported ClinicalTrials.gov record.